Tag: Relypsa

Finance

Morning Alert: Relypsa (NASDAQ:RLYP), American Airlines Group Inc. (NASDAQ:AAL), Isis Pharmaceuticals (NASDAQ:ISIS), Penford Corporation (NASDAQ:PENX), Nabors Industries Ltd. (NYSE:NBR)

Relypsa, Inc. (NASDAQ:RLYP) SVP Lance Berman sold 20,000 shares of the company’s stock on the open market in a transaction dated Monday, August 25th. The stock was sold at an average price of $25.89, for a total transaction of $517,800.00. Following the completion of the transaction, the senior vice president now directly owns 7,500 shares in the company, valued at approximately $194,175. Relypsa, Inc. (NASDAQ:RLYP) … Continue reading Morning Alert: Relypsa (NASDAQ:RLYP), American Airlines Group Inc. (NASDAQ:AAL), Isis Pharmaceuticals (NASDAQ:ISIS), Penford Corporation (NASDAQ:PENX), Nabors Industries Ltd. (NYSE:NBR)

Richard Atkins
Finance

Morning Alert: Tekmira Pharmaceuticals (NASDAQ:TKMR), Novavax (NASDAQ:NVAX), Relypsa (NASDAQ:RLYP), VMware, Inc. (NYSE:VMW), Cameron International (NYSE:CAM)

Equities researchers at Leerink Swann began coverage on shares of Tekmira Pharmaceuticals (NASDAQ:TKMR) in a research report issued on Monday. Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) belongs to Healthcare sector. Its weekly performance is -18.28%. On last trading day company shares ended up $19.45. Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) distance from 50-day simple moving average (SMA50) is 48.15%. Stock analysts at Citigroup Inc. assumed coverage on shares of Novavax (NASDAQ:NVAX) in … Continue reading Morning Alert: Tekmira Pharmaceuticals (NASDAQ:TKMR), Novavax (NASDAQ:NVAX), Relypsa (NASDAQ:RLYP), VMware, Inc. (NYSE:VMW), Cameron International (NYSE:CAM)

Kevin Long
Finance

Biotech Decliners: Insmed Incorporated (NASDAQ:INSM), 22nd Century Group Inc (NYSEMKT:XXII), Concert Pharmaceuticals Inc (NYSE:JMPC), Relypsa Inc (NASDAQ:RLYP)

Insmed Incorporated (NASDAQ:INSM) on May 13, 2014 announces that multiple posterpresentations reporting data on ARIKAYCE(TM), or liposomal amakacinfor inhalation, for the treatment of Pseudomonas aeruginosainfections in cystic fibrosis (CF) patients and for the treatment ofpatients with treatment-resistant nontuberculous mycobacterial (NTM)lung infections will be presented at the American Thoracic SocietyAnnual Meeting 2014, taking place May 16-21 in San Diego, California. Insmed Incorporated (NASDAQ:INSM) stock performance was … Continue reading Biotech Decliners: Insmed Incorporated (NASDAQ:INSM), 22nd Century Group Inc (NYSEMKT:XXII), Concert Pharmaceuticals Inc (NYSE:JMPC), Relypsa Inc (NASDAQ:RLYP)

Kevin Long
Finance

Healthcare Bullish Stocks: Reliv International (NASDAQ:RELV), Flexion Therapeutics (NASDAQ:FLXN), Relypsa Inc (NASDAQ:RLYP), Sucampo Pharmaceuticals (NASDAQ:SCMP)

Reliv International, Inc (NASDAQ:RELV) reported net sales of $14.5 million for the first quarter of 2014, compared to net sales of $18.9 million for the first quarter of 2013. Net sales in the United States declined by 29.2 percent for the quarter compared to the same quarter in 2013. Reliv International, Inc (NASDAQ:RELV) stock performance was 7.37% in last session and finished the day at … Continue reading Healthcare Bullish Stocks: Reliv International (NASDAQ:RELV), Flexion Therapeutics (NASDAQ:FLXN), Relypsa Inc (NASDAQ:RLYP), Sucampo Pharmaceuticals (NASDAQ:SCMP)

Jason Knox
BioTech

Biotech Stocks Touching New Highs: Relypsa Inc. (NASDAQ:RLYP), Vanda Pharmaceuticals (NASDAQ:VNDA), OHR Pharmaceutical (NASDAQ:OHRP), Xencor (NASDAQ:XNCR)

Relypsa, Inc. (NASDAQ:RLYP) is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. Relypsa Inc. (NASDAQ:RLYP) stock performance was 2.66% in last session and finished the day at $43.62. Traded volume was 126,739.00 shares in the last session and the average volume of the stock remained 113,686.00 shares. Relypsa … Continue reading Biotech Stocks Touching New Highs: Relypsa Inc. (NASDAQ:RLYP), Vanda Pharmaceuticals (NASDAQ:VNDA), OHR Pharmaceutical (NASDAQ:OHRP), Xencor (NASDAQ:XNCR)

Mark DeFrance